The current situation and future of anticoagulant therapy for sepsis

doi:10.3877/cma.j.jssn.2096-1537.2016.03.004

Abstract

Abstract:

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection and is usually associated with coagulation dysfunction. Sepsis induced microvascular thrombosis works as a ″double-edged sword″. The local microvascular thrombosis can play a role of host defense as immunothrombosis and promote the removal of pathogenic microorganisms. In contrast, disseminated intravascular thrombosis is an important pathogenesis of sepsis related multiple organ dysfunction, which provides a theoretical basis for the anticoagulation therapy. Although there is controversy about the clinical trials on the anticoagulation therapy for sepsis, the clinical value of anticoagulation therapy can not be completely denied. We should comprehensive evaluate the coagulation function of septic patients to find the optimal timing for anticoagulant therapy and the optimal patient group who may get benefit from the anticoagulant therapy, and further optimize the strategy of anticoagulant therapy for septic patients.

Key words: Sepsis, Coagulation dysfunction, Microvascular thrombosis, Anticoagulant therapy, Heparin

Zhidan Zhang, Xin Li, Xiaochun Ma. The current situation and future of anticoagulant therapy for sepsis[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2016, 02(03): 156-161.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://icu.cma-cmc.com.cn/EN/10.3877/cma.j.jssn.2096-1537.2016.03.004

https://icu.cma-cmc.com.cn/EN/Y2016/V02/I03/156

References 48

[1]	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8):801–810.
[2]	Okamoto K, Tamura T, Sawatsubashi Y. Sepsis and disseminated intravascular coagulation[J]. J Intensive Care, 2016, 4:23.
[3]	Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock; 2012[J]. Crit Care Med, 2013, 41(2):580–637.
[4]	Oda S, Aibiki M, Ikeda T, et al. The Japanese guidelines for the management of sepsis[J]. J Intensive Care, 2014, 2(1):55.
[5]	Angus DC, van der Poll T. Severe Sepsis and Septic Shock[J]. N Engl J Med, 2013, 369(9):840–851.
[6]	Wiersinga WJ, Leopold SJ, Cranendonk DR, et al. Host innate immune responses to sepsis[J]. Virulence , 2014, 5(1):36–44 .
[7]	Semeraro N, Ammollo CT, Semeraro F, et al. Coagulopathy of Acute Sepsis[J]. Semin Thromb Hemost , 2015, 41(6):650–658.
[8]	Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis[J]. Proc Natl Acad Sci U S A, 2010, 107(36):15880–15885.
[9]	Ammollo CT, Semeraro F, Xu J, Esmon NL, et al. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation[J]. J Thromb Haemost, 2011, 9(9):1795–1803.
[10]	Ito T. PAMPs and DAMPs as triggers for DIC[J]. J Intensive Care, 2014, 2(1):67.
[11]	Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity[J]. Nat Rev Immunol , 2013, 13(1):34–45.
[12]	Seeley EJ, Matthay MA, Wolters PJ. Inflection points in sepsis biology: from local defense to systemic organ injury[J]. Am J Physiol Lung Cell Mol Physiol , 2012, 303(5):355–363.
[13]	Soerensen KE, Olsen HG, Skovgaard K, et al. Disseminated intravascular coagulation in a novel porcine model of severe staphylococcus aureus sepsis fulfills human clinical criteria[J]. J Comp Pathol, 2013, 149(4):463–474.
[14]	Simmons J, Pittet JF. The coagulopathy of acute sepsis[J]. Curr Opin Anaesthesiol, 2015, 28(2):227–236.
[15]	Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial[J]. JAMA, 2003, 290(2):238–247.
[16]	Wunderink RG, Laterre PF, Francois B, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia a randomized trial[J]. Am J Respir Crit Care Med , 2011, 183(11):1561–1568.
[17]	Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial[J]. JAMA, 2001, 286(15):1869–1878.
[18]	Allingstrup M, Wetterslev J, Ravn FB, et al. Antithrombin Ⅲ for critically ill patients[J]. Cochrane Database Syst Rev, 2016, 2:CD005370.
[19]	Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J]. N Engl J Med, 2001, 344(10):699–709.
[20]	Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock[J]. Intensive Care Med, 2004, 30(4):536–555.
[21]	Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death[J]. N Engl J Med, 2005, 353(13):1332–1341.
[22]	Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock[J]. N Engl J Med, 2012, 366(22):2055–2064.
[23]	Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013, 41(2):580–637.
[24]	Vincent JL, Ramesh MK, Ernest D, et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy ofrecombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation[J]. Crit Care Med, 2013, 41(9):2069–2079.
[25]	Yamakawa K, Aihara M, Ogura H, et al. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis[J]. J Thromb Haemost, 2015 , 13(4):508–519.
[26]	Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)[J]. Crit Care Med, 2009, 37(4):1185–1196.
[27]	Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis[J]. Crit Care, 2014, 18(5):563.
[28]	Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis[J]. Crit Care Med, 2015, 43(3):511–518.
[29]	Allen KS, Sawheny E, Kinasewitz GT. Anticoagulant modulation of inflammation in severe sepsis[J]. World J Crit Care Med, 2015, 4(2):105–115.
[30]	Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, et al. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective[J]. BMC Med, 2015, 13:105.
[31]	Umemura Y, Yamakawa K, Ogura H, et al. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials[J]. J Thromb Haemost, 2016, 14(3):518–530.
[32]	Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan[J]. Int J Hematol, 2016, 103(3):253–261.
[33]	Iba T, Saitoh D, Wada H, et al. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey[J]. Crit Care, 2014, 18(5):497.
[34]	Yoshimura J, Yamakawa K, Ogura H, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis[J]. Crit Care, 2015, 19:78.
[35]	Semeraro N, Ammollo CT, Semeraro F, et al. Sepsis, thrombosis and organ dysfunction[J]. Thromb Res, 2012, 129(3):290–295.
[36]	Allam R, Kumar SV, Darisipudi MN, et al. Extracellular histones in tissue injury and inflammation[J]. J Mol Med (Berl), 2014, 92(5):465–472.
[37]	Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis[J]. Nat Med, 2009, 15(11):1318–1321.
[38]	Li Y, Liu Z, Liu B, et al. Citrullinated histone H3: a novel target for the treatment of sepsis[J]. Surgery, 2014, 156(2):229–234.
[39]	Iba T, Hashiguchi N, Nagaoka I, et al. Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction[J]. Intensive Care Med Exp, 2015, 3(1):36.
[40]	Wildhagen KC, García de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis[J]. Blood, 2014, 123(7):1098–1101.
[41]	Wildhagen KC, Ding R, Hao D, Guo R, et al. Treatment with unfractionated heparin attenuates Coagulation and Inflammation in Endotoxemic Mice[J]. Thromb Res, 2011, 128(6):160–165.
[42]	Zhao D, Ding R, Mao Y, et al. Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses[J]. Inflammation, 2012, 35(6):1825–1832.
[43]	Li X, Zheng Z, Li X, et al. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell[J]. Cytokine, 2012, 60(1):114–121.
[44]	Luan ZG, Naranpurev M, Ma XC. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats[J]. Inflammation, 2014, 37(3):924–932.
[45]	Yini S, Heng Z, Xin A, et al. Effect of unfractionated heparin on endothelial glycocalyx in a septic shock model[J]. Acta Anaesthesiol Scand, 2015, 59(2):160–169.
[46]	Wang L, Liu Z, Dong Z, et al. Azurocidin-induced inhibition of oxygen metabolism in mitochondria is antagonized by heparin[J]. Exp Ther Med, 2014, 8(5):1473–1478.
[47]	Iba T, Miki T, Hashiguchi N, et al. Combination of antithrombin and recombinant thrombomodulin modulates neutrophil cell-death and decreases circulating DAMPs levels in endotoxemic rats[J]. Thromb Res, 2014, 134(1):169–173.
[48]	Annane D, Buisson CB, Cariou A, et al. Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial[J]. Ann Intensive Care, 2016, 6(1):43.

Please choose a citation manager

Content to export